Literature DB >> 6803664

Comparative antipseudomonal activity of some newer beta-lactam agents.

D Greenwood, A Eley.   

Abstract

The antipseudomonal activities of cefotaxime, ceftizoxime, ceftazidime, ceftriaxone, cefoperazone, and moxalactam were tested in conventional minimum inhibitory concentration titrations and according to morphological and turbidimetric criteria. Three groups of pseudomonal strains were tested: carbenicillin hypersusceptible, carbenicillin susceptible, and carbenicillin resistant. In minimum inhibitory concentration titrations, the carbenicillin-hypersusceptible strains did not differ greatly in their susceptibility to other beta-lactam agents, although moxalactam appeared to be rather less active than the other drugs. When tested against the remaining strains, ceftazidime was the most active compound, followed by cefoperazone and ceftriaxone. The turbidimetric experiments supported by microscopical observations, all of the agents induced bacterial lysis in the carbenicillin-hypersusceptible strains, but cefoperazone appeared to be less actively bacteriolytic than the rest of the antibiotics. None of the agents was able to prevent growth of the remainder of the Pseudomonas aeruginosa strains in the first few hours of drug exposure, during which time the bacteria elongated to form long filaments. However, the various agents differed in the length of time which elapsed before growth was completely halted. Judged in this way, moxalactam was the most active compound in relation to its minimum inhibitory concentration, but in comparative experiments in which the same concentration of each drug (64 microgram/ml) was used regardless of the minimum inhibitory concentration, ceftazidime appeared to be the most active antibiotic, followed by ceftriaxone and cefotaxime.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6803664      PMCID: PMC181860          DOI: 10.1128/AAC.21.2.204

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  2 in total

1.  Comparison of the responses of Escherichia coli and proteus mirabilis to seven beta-lactam antibodies.

Authors:  D Greenwood; F O'Grady
Journal:  J Infect Dis       Date:  1973-08       Impact factor: 5.226

2.  A twelve channel bacterial growth monitoring system.

Authors:  I P Mackintosh; F O'Grady; D Greenwood; B W Watson; T C Crichton; R Piper; A Ferrer
Journal:  Biomed Eng       Date:  1973-12
  2 in total
  12 in total

1.  Attempted reduction of Abbott MS-2 false-susceptible errors for cefotaxime-resistant Pseudomonas aeruginosa by medium modification.

Authors:  D W Lander; D L Jungkind; L L Stone
Journal:  J Clin Microbiol       Date:  1987-04       Impact factor: 5.948

2.  High-pressure liquid chromatographic analysis of ceftazidime in serum and urine.

Authors:  J S Leeder; M Spino; A M Tesoro; S M MacLeod
Journal:  Antimicrob Agents Chemother       Date:  1983-11       Impact factor: 5.191

3.  Comparison of ceftazidime with cefamandole for therapy of community-acquired pneumonia.

Authors:  J C Engle; P W Lifland; C J Schleupner
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

4.  Double-blind, prospective, multicenter trial comparing ceftazidime with moxalactam in the treatment of serious gram-negative infections.

Authors:  M Joshi; W C Anthony; J H Tenney; G L Drusano; E S Caplan; H C Standiford; A Henson; J W Warren
Journal:  Antimicrob Agents Chemother       Date:  1986-07       Impact factor: 5.191

Review 5.  Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  D M Richards; R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-06       Impact factor: 9.546

6.  Evaluation of ceftriaxone and other antibiotics against Escherichia coli, Pseudomonas aeruginosa, and Streptococcus pneumoniae under in vitro conditions simulating those of serious infections.

Authors:  G Satta; G Cornaglia; G Foddis; R Pompei
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

7.  False-susceptible results from the MS-2 system used for testing resistant Pseudomonas aeruginosa against two third-generation cephalosporins, moxalactam and cefotaxime.

Authors:  L L Stone; D L Jungkind
Journal:  J Clin Microbiol       Date:  1983-08       Impact factor: 5.948

Review 8.  Clinical pharmacokinetics of the third generation cephalosporins.

Authors:  L Balant; P Dayer; R Auckenthaler
Journal:  Clin Pharmacokinet       Date:  1985 Mar-Apr       Impact factor: 6.447

Review 9.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

10.  Use of ceftazidime in the therapy of serious infections, including those due to multiresistant organisms.

Authors:  N Clumeck; Y Van Laethem; B Gordts; N Jaspar; J P Butzler
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.